Royalty Pharma plc is in the spotlight for several developments. It has announced multiple dividend payments, including a second quarter 2025 payment of
$0.22 per share, consistent with previous quarters. The company also surged after an
acquisition announcement. A notable number of
major investment players, such as Cerity Partners and Guggenheim Capital, have offloaded their shares in the company. Conversely, a series of prominent investment institutions, including Barclays and Bank of America Securities (which reaffirmed their buy rating), have increased their holdings or bought into Royalty Pharma. The organization has also scheduled a critical Q1 2025 earnings release. The company's stock has seen increased trading activity as its
RS Rating jumped to 92. Its pricing target was set at $42.50 by brokerages. Additionally, Royalty Pharma is planning to back a groundbreaking Lupus treatment in late-stage trials, involving a
$250 million deal. Lastly, the company was named the best defensive stock amid market volatility and one of the most undervalued healthcare stocks to buy according to analysts. However, not all developments paint a rosy picture. For instance, Royalty Pharma reportedly missed Q4 revenue estimates.
Royalty Pharma Stocks News Analytics from Tue, 02 Jul 2024 07:00:00 GMT to Sat, 26 Apr 2025 17:28:41 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor -4
